Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
4
Neutral
8
Bullish
2
Bearish
14
Neutral
8
Bullish
24
Bearish
10
Neutral
0
Bullish
22
Discovery themes featuring this stock
Windlas Biotech Limited is a vertically integrated Indian pharmaceutical company focused on formulation development, commercial GMP manufacturing and marketing across three strategic verticals: Generic Formulations CDMO, Trade Generics & Institutional sales, and Exports, with five WHO‑GMP plants in Dehradun and a recently commissioned injectable facility driving diversification across dosage forms.
Windlas delivered record revenues for the twelfth consecutive quarter: 9MFY26 revenue of Rs 666 crore and Q3FY26 revenue of Rs 233 crore, reflecting YoY growth of 19% and 20% respectively, driven by CDMO strength, rising injectable contributions and Plant‑2 extension benefiting utilization and volumes across core businesses.
The company owns intellectual property for ~99% of products it supplies as a CDMO, serves 757 customers and caters to 5,582 products, highlighting deep formulation expertise in complex generics and fixed‑dose combinations that create customer stickiness and higher margin mix, positioning Windlas Biotech as a go‑to partner for branded domestic formulators.
Balance sheet and cash generation are healthy: Windlas reported net‑debt free metrics, Rs 213 crore liquidity, positive operating cash flows (Rs 68 crore FY25) and strong return ratios (ROE ~25%, ROCE ~27%), supporting near‑term capex for Plant‑6 while maintaining financial discipline and the capacity to fund opportunistic investments.
Exports and trade generics are accelerating: exports grew 29% in 9MFY26 and 36% in Q3FY26 with penetration into RoW and semi‑regulated markets, while trade generics (400 brands) target tier‑2/3 expansion and institutional tenders such as Jan Aushadhi, offering multi‑front growth levers beyond CDMO volumes.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,774 Cr
Low Risk
26.7
36.7
2.5
3.1
1,095.00
699.35
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2366.60 | 2,011 Cr | 37.55 | 5.58 | 0.47 | 15.45 | 14.34 | 8.48 | ||
3190.90 | 1,974 Cr | 41.03 | 6.00 | 0.05 | 14.62 | 15.37 | 8.81 | ||
228.50 | 1,974 Cr | 39.89 | 1.43 | 0.00 | 3.57 | 4.36 | 2.47 | ||
802.20 | 1,785 Cr | 49.46 | 5.50 | 0.00 | 9.40 | 12.54 | 7.50 | ||
857.35 | 1,774 Cr | 26.69 | 3.05 | 0.73 | 11.44 | 14.90 | 7.32 | ||
899.75 | 1,480 Cr | 45.40 | 5.50 | 0.03 | 11.73 | 15.97 | 5.83 | ||
510.50 | 1,476 Cr | 22.88 | 3.99 | 0.96 | 17.42 | 23.31 | 11.38 | ||
| Median: 7 Co. | — | 857.35 | 1,785 Cr | 39.89 | 5.50 | 0.05 | 11.73 | 14.90 | 7.50 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Windlas Biotech Ltd (WINDLAS) is currently trading at 857.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Windlas Biotech Limited is a vertically integrated Indian pharmaceutical company focused on formulation development, commercial GMP manufacturing and marketing across three strategic verticals: Generic Formulations CDMO, Trade Generics & Institutional sales, and Exports, with five WHO‑GMP plants in Dehradun and a recently commissioned injectable facility driving diversification across dosage forms. Windlas delivered record revenues for the twelfth consecutive quarter: 9MFY26 revenue of Rs 666 crore and Q3FY26 revenue of Rs 233 crore, reflecting YoY growth of 19% and 20% respectively, driven by CDMO strength, rising injectable contributions and Plant‑2 extension benefiting utilization and volumes across core businesses. The company owns intellectual property for ~99% of products it supplies as a CDMO, serves 757 customers and caters to 5,582 products, highlighting deep formulation expertise in complex generics and fixed‑dose combinations that create customer stickiness and higher margin mix, positioning Windlas Biotech as a go‑to partner for branded domestic formulators. Balance sheet and cash generation are healthy: Windlas reported net‑debt free metrics, Rs 213 crore liquidity, positive operating cash flows (Rs 68 crore FY25) and strong return ratios (ROE ~25%, ROCE ~27%), supporting near‑term capex for Plant‑6 while maintaining financial discipline and the capacity to fund opportunistic investments. Exports and trade generics are accelerating: exports grew 29% in 9MFY26 and 36% in Q3FY26 with penetration into RoW and semi‑regulated markets, while trade generics (400 brands) target tier‑2/3 expansion and institutional tenders such as Jan Aushadhi, offering multi‑front growth levers beyond CDMO volumes.
Over the past 52 weeks, Windlas Biotech Ltd has traded between a low of ₹699.35 and a high of ₹1,095.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Windlas Biotech Ltd has a market capitalization of approximately 1,773.68. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Windlas Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 26.69 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,773.68 Cr, Windlas Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Windlas Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Windlas Biotech Ltd is 26.69. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Windlas Biotech reported FY26 revenue of ₹904 crore, up 19% year on year.
Regulatory/Compliance Filing
Windlas Biotech Ltd submitted combined voting results and scrutinizer's report for the AGM held on 2026-07-23; all resolutions passed, including approval of FY2025-26 financials and final dividend of Rs.6.30/share.
Dividend
Windlas Biotech submitted combined voting results and scrutinizer's report for the 25th AGM held on 2026-07-23. All resolutions were passed and a final dividend of Rs.6.30 per equity share for FY2025-26 was declared.
Regulatory/Compliance Filing
Windlas Biotech Ltd submitted combined voting results and the Scrutinizer's Report for the 25th AGM held on 2026-07-23; all resolutions passed and a final dividend of Rs.6.30 per share for FY2025-26 was declared.
Regulatory/Compliance Filing
Windlas Biotech Ltd filed consolidated voting results and the Scrutinizer's report for its 25th AGM held on 2026-07-23; all resolutions were passed and a final dividend of Rs.6.30 per share for FY2025-26 was declared.
AGM/EGM Notice
Windlas Biotech Ltd held its 25th AGM on 2026-07-23; adopted audited standalone and consolidated FY26 financials; declared final dividend of Rs.6.30/share; re-appointed directors; ratified cost auditor remuneration; appointed an independent director.
AGM/EGM Notice
Windlas Biotech held its 25th AGM on 2026-07-23 via VC; adopted audited standalone & consolidated financials for FY2025-26; declared final dividend of Rs.6.30/share; approved reappointments and appointment of an independent director.
